7h agoInvesting.com Analyst RatingsBULLISH 61Analyst
Canaccord raises Definium Therapeutics price target on trial results
Canaccord raises Definium Therapeutics price target on trial results
Archived explainer. For the current picture see today's DFTX page.
Why Is DEFINIUM THERAPEUTIC (DFTX) Stock Down Today?
By the Top Tier Newswire AI Desk · September 15, 2026 at 10:22 AM ET · reviewed against 18 wire stories
DEFINIUM THERAPEUTIC (DFTX) is down -5.44% in the latest session. Our newswire has captured 18 stories on DFTX across 11 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why DFTX stock is down today
Definium Therapeutics (DFTX) fell 5.44% to $38.06 in morning trade after opening with a modest 0.8% gap up. The stock reversed sharply from a session high of $40.75 to a low of $37.93, driven by a combination of profit-taking and broader market sentiment shifts following recent positive trial data. Despite multiple analyst upgrades and a strong headline event, the stock struggled to maintain upward momentum.
What Happened
Definium announced topline results from its Panorama Phase 3 study of DT120 ODT, a fast-dissolving LSD-based tablet for generalized anxiety disorder. The trial met its primary endpoint, prompting the company to describe the results as showing "unprecedented efficacy." The FDA has already granted DT120 Breakthrough Therapy Designation for both major depressive disorder and generalized anxiety disorder. The company plans to file a pre-NDA meeting in Q4 2026 and an NDA in the first half of 2027.
Analysts responded with several upgrades. Canaccord raised its price target, as did H.C. Wainwright and Oppenheimer. BofA also increased its price target to $91 from $75. These analyst actions were widely reported and contributed to the stock's prior rally. However, the recent session saw a reversal as the market digested the news and key insiders sold shares in recent months.
What The Data Shows
The stock opened at $40.56 but fell through the day to $38.01, with a volume of 0.7 million shares, about 30% of the 3-month average. Over the last 8 sessions, the stock had risen 11.2% from $38.90 to $43.24. However, the 52-week tape recorded 19 fresh 52-week lows on September 15. Insiders, including the CEO and CFO, sold shares totaling $3.3 million in the last 90 days. Unusual options activity showed two notable prints, with put premium outpacing call premium by $640,000.
What To Watch
Definium has no upcoming earnings report to monitor. Investors should continue to watch analyst coverage breadth and any new developments in the DT120 regulatory timeline, particularly the pre-NDA filing in Q4 2026.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
DFTX by the numbers
Last: $38.06Session: -5.44%7 sessions: -2.40%Coverage: 18 stories / 11 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $5.2B52w: $8.77 to $49.70
The headlines behind the move
8h agoInvesting.com Analyst RatingsBULLISH 63Analyst
H.C. Wainwright reiterates Definium stock rating on positive trial data
H.C. Wainwright reiterates Definium stock rating on positive trial data
1d agoThe FlyBULLISH 63Analyst
Definium Therapeutics price target raised to $75 from $70 at Oppenheimer
1d agoSeeking AlphaBULLISH 59Product/PR
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder - Slideshow
2026-09-14. The following slide deck was published by Definium Therapeutics, Inc.
1d agoThe FlyBULLISH 61Analyst
Definium Therapeutics price target raised to $91 from $75 at BofA
1d agoStocktwits NewsBULLISH 67Product/PR
DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug
The company said that the Panorama trial of DT120, a fast-dissolving tablet form of the psychedelic drug lysergide, or LSD, met its main goal in adults with generalized anxiety disorder.
1d agoSeeking AlphaBULLISH 73Product/PR
Definium rises as LSD pill achieves primary goal in late-stage trial for anxiety
Definium Therapeutics shares rise after phase 3 DT120 (LSD) results hit endpoints in anxiety. Pre-NDA Q4, filing H1 2027. Read more here.
1d agoBarron'sBULLISH 73Product/PR
First Marijuana, Then Peptides. Why Psychedelics Are Wall Street’s Next Big Trip.
Definium Therapeutics advances the case for medical LSD after reporting positive late-stage trial data for its experimental drug, DT120.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on DFTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier DFTX move explainers: 2026-09-15 · 2026-09-14